Cytomed Therapeutics signs research agreements in China and Taiwan

CytoMed Therapeutics has entered into a Heads of Agreement – HOA – with CytoMed Therapeutics China, a company incorporated in Hong Kong and a Memorandum of Understanding – MOU – with BioNex Solutions. The HOA forms a collaborative effort between CytoMed and CytoMed China to explore and investigate the safety, tolerability, potency, and efficacy of CytoMed’s proprietary allogeneic gamma delta T cells for the treatment of various cancers – including solid tumors – in human subjects through an investigator-initiated trial in the People’s Republic of China. The IIT is to be initiated through an entity to be incorporated in Chongqing, a municipality directly under the Central Government. CytoMed will provide technical assistance in the planning and conduct of the clinical trial and will grant CytoMed China, a loan of up to an aggregate of S$1M over three years. CytoMed is granted a first right of refusal to acquire a majority interest in CytoMed China, a new set-up by independent third parties. CytoMed has recently entered a MOU with BioNex Solutions, a company incorporated/headquartered in Taiwan, Republic of China, to explore the potential application of CytoMed’s unmodified allogeneic gamma delta T cells in patients who have no authorized therapy options for their relevant medical conditions. BioNex is a private company with patient-centric care facilities, targeting unmet medical needs in cancer treatment.